SCHEMBL8737474

SCHEMBL8737474

Cc1ccc(Oc2ccc3c(c2)C(=O)NC3)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 3/20 0.52
DYRK1B Q9Y463 2/20 0.52
FYN P06241 1/20 0.52
PARP10 Q53GL7 2/20 0.47
PARP1 P09874 1/20 0.47
NTRK2 Q16620 2/20 0.46
TYRO3 Q06418 1/20 0.46
NTRK1 P04629 2/20 0.45
FLT3 P36888 2/20 0.45
GSK3B P49841 2/20 0.45
JAK2 O60674 1/20 0.45
MET P08581 1/20 0.45
FGFR1 P11362 1/20 0.45
PRKACA P17612 1/20 0.45
KDR P35968 1/20 0.45
MAP2K2 P36507 1/20 0.45
MAP2K1 Q02750 1/20 0.45
MST1R Q04912 1/20 0.45
NTRK3 Q16288 1/20 0.45
CAMK1D Q8IU85 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6014812 0.88 CLK4 (0.48) CLK4DYRK1BFYNPARP10PARP1
SCHEMBL149199 0.81 PARP10 (0.68) CLK4DYRK1BFYNPARP10PARP1
SCHEMBL30560110 0.81 PARP10 (0.68) CLK4DYRK1BFYNPARP10PARP1
SCHEMBL31069587 0.80 PDE3B (0.53) CLK4DYRK1BFYNNTRK2TYRO3
SCHEMBL2849831 0.80 PDE3B (0.53) CLK4DYRK1BFYNNTRK2TYRO3
SCHEMBL19187116 0.79 CLK4 (0.74) CLK4DYRK1BFYNPARP10PARP1
SCHEMBL29985572 0.79 CLK4 (0.74) CLK4DYRK1BFYNPARP10PARP1
SCHEMBL15553470 0.77 NTRK2 (0.51) CLK4DYRK1BFYNPARP10PARP1
SCHEMBL10113037 0.76 CLK4 (0.47) CLK4DYRK1BFYNPARP10PARP1
SCHEMBL20992951 0.76 CLK4 (0.47) CLK4DYRK1BFYNNTRK2TYRO3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120129893-A1 Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas DUMAS JACQUES (US) 2012-05-24 US disclosed
US-20120129893-A1 Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas DUMAS JACQUES (US) 2012-05-24 US disclosed
US-20070244120-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BAYER HEALTHCARE LLC 2007-10-18 US disclosed
US-20070244120-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BAYER HEALTHCARE LLC 2007-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244120-A1 INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS BRAF, RAF1, ARAF CLK4 541/4885DYRK1B 927/4885FYN 1344/4885
US-20120129893-A1 Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas BRAF, RAF1, ARAF CLK4 541/4885DYRK1B 927/4885FYN 1344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.